This study evaluated the blood levels of atazanavir according to a genetic makeup for CYP3A5
(cytochrome P450 3A5, an enzyme that metabolizes atazanavir). The hypothesis was that people
with a slow-metabolizing genotype would have higher blood levels of atazanavir compared to
people with the normal metabolizing genotype.
Phase:
Phase 4
Details
Lead Sponsor:
University of Colorado, Denver
Collaborator:
National Institute of Allergy and Infectious Diseases (NIAID)
Treatments:
Atazanavir Sulfate HIV Protease Inhibitors Protease Inhibitors